HER2/neu Vaccine Results Spurs Phase III Planning by Apthera, Inc.SCOTTSDALE, Ariz. -- Col. George E. Peoples, M.D., Chief of Surgical Oncology at Brooke Army Medical Center Brooke Army Medical Center (BAMC) at Fort Sam Houston, San Antonio is part of the United States Army Health Services Command. It is a University of Texas Health Science Center and USUHS teaching hospital and contains the Army Burn Center. in San Antonio, TX will be presenting the results of a 200 patient Phase II study of a HER2/neu vaccine (E75) for the prevention of recurrence in high risk breast cancer patients at the 29th Annual San Antonio Breast Cancer Symposium, the premier breast cancer educational and scientific event. Dr. Peoples will present positive interim analysis of the Phase II study of E75 on Thursday, December 14th at 10:30am (CST) at the Georgia and Henry B. Gonzalez Convention Center The Henry B. Gonzalez Convention Center is located in downtown San Antonio along the banks of the San Antonio River Walk. The facility is the central component of the city’s successful convention industry. The center, named for the late US congressman Henry B. in San Antonio, Texas “San Antonio” redirects here. For other uses, see San Antonio (disambiguation). San Antonio is the second most populous city in Texas, the third most populous metropolitan area in Texas, and is the seventh most populous city in the United States. As of the 2006 U.S. . Based on the advanced development stage of this product and the promising Phase I and Phase II results, Apthera, Inc. has exclusively licensed E75 from The Henry M. Jackson Foundation for the Advancement of Military Medicine The Henry Jackson Foundation for the Advancement of Military Medicine (HJF) is a non-profit organization whose purpose is to investigate any malady that can affect United States military personnel and their dependents. , Inc. and another major academic institution. About the Company Apthera, Inc. is a private company established in July, 2005 to develop and commercialize advanced-stage clinical programs in cancer immunotherapy licensed from renowned academic institutions. Apthera's initial focus is on funding and completing the final phases of development of E75 (NeuVax[TM]). Apthera's licensed technology is based on the use of single immunostimulatory peptides, such as E75, and peptide combinations to activate multiple "killer" T-cell clones against multiple tumor antigen epitopes. This new adjunct therapy, used in a clinical setting of minimal residual disease, will result in less disease recurrence and improved long-term cancer survival. Apthera has patents and strong proprietary protection on the naturally-presented human leukocyte antigen human leukocyte antigen n. Abbr. HLA A gene product of the major histocompatibility complex; these antigens have been shown to have a strong influence on human allotransplantation, transfusions in refractory patients, and certain disease (HLA HLA human leukocyte antigens. HLA abbr. human leukocyte antigen HLA (human leuckocyte antigen) ) peptides, methods of use, compositions, modifications, and processes. NeuVax[TM] is being readied for Phase III studies and indicated for the adjuvant treatment of breast and prostate cancers, and other HER2/neu-expressing tumors. Based upon the early success achieved in the clinic, the company now plans an end-of-Phase II meeting with FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. to discuss a Special Protocol Assessment (SPA) and the design and conduct of a large, randomized, pivotal Phase III registration study for the breast cancer indication. This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. These statements are not historical facts and are subject to risks and uncertainties which could cause actual results and the timing of certain events to differ materially from those set forth in or implied herein including, without limitation, risks associated with clinical development, regulatory approvals, product commercialization, intellectual property claims litigation and other risks associated with the Company's proposed activities. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion